<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02275468</url>
  </required_header>
  <id_info>
    <org_study_id>SF-2009-Ⅲ-01</org_study_id>
    <nct_id>NCT02275468</nct_id>
  </id_info>
  <brief_title>Fu-zheng-qu-zhuo Oral Liquid Improves Renal Function in Patients of CKD Stage 3 and 4</brief_title>
  <official_title>Fu-zheng-qu-zhuo Oral Liquid Combined With Integrated Therapy Improves Renal Function in Patients of Chronic Kidney Disease Stage 3 and 4，a Randomized Placebo-Control Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fangshan Hospital of Traditional Chinese Medicine,</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      a prospective, multicenter (outpatient clinics of the three participating hospitals in
      Beijing), double blinded and randomized placebo-controlled study.

      The study consisted of a 2-week run-in period and a 12-month treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>composite end point</measure>
    <time_frame>12 month after the treatmnet and 3 years of the follow up time</time_frame>
    <description>end stage renal disease (defined by the need for long-term dialysis or renal transplantation, or eGFR＜15ml/min) and all cause of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the slope of the eGFR versus observation time</measure>
    <time_frame>12 month after the treatment</time_frame>
    <description>the decline of eGFR per-year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Stage 3 Chronic Kidney Disease</condition>
  <condition>Stage 4 Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients of Control Group received FZQZ-Placebo 20ml every time, and three times a day combined with integrated therapy.The integrated therapy was as follows: (1)low-protein dietary with sufficient calorie supply.(2) Anti-hypertensive agents to achieve a systolic blood pressure of less than 140 mm Hg and a diastolic blood pressure of less than 90 mmHg.(3)Anti-hyperlipidemic agentsas necessary to achieve low-density lipoprotein cholesterol（LDL-CH）less than 2.6mmol/L and triglycerides less than1.7mmol/L.（4）Patients with Diabetes Mellitus received insulin or oral hypoglycemic agents to achieve HbA1c 6.5～8.0%. (5)Received Sodium Bicarbonate as necessary to achieve serum HCO3-≥22mmol/L.(6) Received ferrous succinate, folic acid, and erythropoietin to achieve HB 90~110g/L.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fu-zheng-qu-zhuo oral liquid Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients of FZQZ Group received Fu-zheng-qu-zhuo (FZQZ) oral liquid 20ml every time, and three times a day combined with integrated therapy. The integrated therapy was same to Control Group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fu-zheng-qu-zhuo (FZQZ) oral liquid</intervention_name>
    <description>FZQZ oral liquid is a herbal medicine, composed of astragalus, angelica root, rhubarb, etc, with the effect of reinforcing Qi and activating blood, dissolving dampness and downbearing turbid.</description>
    <arm_group_label>Fu-zheng-qu-zhuo oral liquid Group</arm_group_label>
    <other_name>FZQZ oral liquid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (1) Signed informed consent and aged from 18 to 75 years old. (2) Chronic renal diseases
        with Glomerular Filtration Rate (GFR) estimated using the CKD Epidemiology Collaboration
        (CKD-EPI) equation between 15 and 59 ml/min per 1.73 m2 on at least 2 dates separated by at
        least 90 days but no more than 6 month (the CKD defining window period). (3)Not received
        other TCM treatment for at least 2 weeks.

        Exclusion Criteria:

        (1) 50% increase in serum creatinine occurring within 2 month before screening. (2)
        Immediate need for dialysis. (3) Myocardial infarction or cerebrovascular accident in the 6
        month preceding the trial. (4) Connective-tissue disease, obstructive uropathy and renal
        transplantation. (5) Patients with severe disease in other organs or cancer, psychotic
        diseases, and active tuberculosis. (6) Treatment with corticosteroid and immunosuppressive
        agents in recent 3 month. Hemoglobin (Hb) less than 80 g/L. (7) Diabetes Mellitus with
        uncontrolled Blood Sugar ( glycated hemoglobin （HbA1c） ＞8.0%). (8) Enrolled in other
        trials. (9) Women in pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Wang</last_name>
    <role>Study Chair</role>
    <affiliation>Guang anmen Hospital, China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guang anmen Hospital, China Academy of Chinese Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fangshan Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guang'an Men Hospital South</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <last_update_submitted>October 23, 2014</last_update_submitted>
  <last_update_submitted_qc>October 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>eGFR slope</keyword>
  <keyword>Herbal medicine Fu-zheng-qu-zhuo Oral liquid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

